Literature DB >> 24477561

Rotary bioreactor culture can discern specific behavior phenotypes in Trk-null and Trk-expressing neuroblastoma cell lines.

Robert A Redden1, Radhika Iyer, Garrett M Brodeur, Edward J Doolin.   

Abstract

Neuroblastoma is characterized by biological and genetic heterogeneity that leads to diverse, often unpredictable, clinical behavior. Differential expression of the Trk family of neurotrophin receptors strongly correlates with clinical behavior; TrkA expression is associated with favorable outcome, whereas TrkB with unfavorable outcome. Neuroblastoma cells cultured in a microgravity rotary bioreactor spontaneously aggregate into tumor-like structures, called organoids. We wanted to determine if the clinical heterogeneity of TrkA- or TrkB-expressing neuroblastomas was reflected in aggregation kinetics and organoid morphology. Trk-null SY5Y cells were stably transfected to express either TrkA or TrkB. Short-term aggregation kinetics were determined by counting the number of single (non-aggregated) viable cells in the supernatant over time. Organoids were harvested after 8 d of bioreactor culture, stained, and analyzed morphometrically. SY5Y-TrkA cells aggregated significantly slower than SY5Y and SY5Y-TrkB cells, as quantified by several measures of aggregation. SY5Y and TrkB cell lines formed irregularly shaped organoids, featuring stellate projections. In contrast, TrkA cells formed smooth (non-stellate) organoids. SY5Y organoids were slightly smaller on average, but had significantly larger average perimeter than TrkA or TrkB organoids. TrkA expression alone is sufficient to dramatically alter the behavior of neuroblastoma cells in three-dimensional, in vitro rotary bioreactor culture. This pattern is consistent with both clinical behavior and in vivo tumorigenicity, in that SY5Y-TrkA represents a more differentiated, less aggressive phenotype. The microgravity bioreactor is a useful in vitro tool to rapidly investigate the biological characteristics of neuroblastoma and potentially to assess the effect of cytotoxic as well as biologically targeted drugs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24477561      PMCID: PMC4243461          DOI: 10.1007/s11626-013-9716-z

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol Anim        ISSN: 1071-2690            Impact factor:   2.416


  27 in total

1.  Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones.

Authors:  J L Biedler; S Roffler-Tarlov; M Schachner; L S Freedman
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

2.  Molecular dissection of TrkA signal transduction pathways mediating differentiation in human neuroblastoma cells.

Authors:  A Eggert; N Ikegaki; X Liu; T T Chou; V M Lee; J Q Trojanowski; G M Brodeur
Journal:  Oncogene       Date:  2000-04-13       Impact factor: 9.867

3.  Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells.

Authors:  Angelika Eggert; Michael A Grotzer; Naohiko Ikegaki; Xing-ge Liu; Audrey E Evans; Garrett M Brodeur
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

4.  Resistance to chemotherapy mediated by TrkB in neuroblastomas.

Authors:  Ruth Ho; Angelika Eggert; Tomoro Hishiki; Jane E Minturn; Naohiko Ikegaki; Patricia Foster; Anna Marie Camoratto; Audrey E Evans; Garrett M Brodeur
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

Review 5.  Neuroblastoma: biological insights into a clinical enigma.

Authors:  Garrett M Brodeur
Journal:  Nat Rev Cancer       Date:  2003-03       Impact factor: 60.716

6.  Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas.

Authors:  T Suzuki; E Bogenmann; H Shimada; D Stram; R C Seeger
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

7.  Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma.

Authors:  A Nakagawara; M Arima-Nakagawara; N J Scavarda; C G Azar; A B Cantor; G M Brodeur
Journal:  N Engl J Med       Date:  1993-03-25       Impact factor: 91.245

8.  A novel preclinical model of human malignant melanoma utilizing bioreactor rotating-wall vessels.

Authors:  L L Licato; V G Prieto; E A Grimm
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-03       Impact factor: 2.723

9.  Permanent phenotypic and genotypic changes of prostate cancer cells cultured in a three-dimensional rotating-wall vessel.

Authors:  H W Rhee; H E Zhau; S Pathak; A S Multani; S Pennanen; T Visakorpi; L W Chung
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-03       Impact factor: 2.723

10.  FAK is a critical regulator of neuroblastoma liver metastasis.

Authors:  Sora Lee; Jingbo Qiao; Pritha Paul; Kathleen L O'Connor; Mark B Evers; Dai H Chung
Journal:  Oncotarget       Date:  2012-12
View more
  4 in total

1.  An Air Bubble-Isolating Rotating Wall Vessel Bioreactor for Improved Spheroid/Organoid Formation.

Authors:  Michael A Phelan; Anthony L Gianforcaro; Jonathan A Gerstenhaber; Peter I Lelkes
Journal:  Tissue Eng Part C Methods       Date:  2019-08       Impact factor: 3.056

2.  Transcriptome profiling reveals the role of ZBTB38 knock-down in human neuroblastoma.

Authors:  Jie Chen; Chaofeng Xing; Li Yan; Yabing Wang; Haosen Wang; Zongmeng Zhang; Daolun Yu; Jie Li; Honglin Li; Jun Li; Yafei Cai
Journal:  PeerJ       Date:  2019-01-24       Impact factor: 2.984

3.  Patient-derived organoids (PDOs) as a novel in vitro model for neuroblastoma tumours.

Authors:  P Fusco; B Parisatto; E Rampazzo; L Persano; C Frasson; A Di Meglio; A Leslz; L Santoro; B Cafferata; A Zin; E Cimetta; G Basso; M R Esposito; G P Tonini
Journal:  BMC Cancer       Date:  2019-10-21       Impact factor: 4.430

4.  Arsenic trioxide induces cell cycle arrest and affects Trk receptor expression in human neuroblastoma SK-N-SH cells.

Authors:  Xilin Xiong; Yang Li; Ling Liu; Kai Qi; Chi Zhang; Yueqin Chen; Jianpei Fang
Journal:  Biol Res       Date:  2018-06-13       Impact factor: 5.612

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.